Santhera Presents Clinical Data of Catena® in Duchenne Muscular Dystrophy at the 2011 Congress of the World Muscle Society
Liestal, Switzerland, October 19, 2011 - Santhera Pharmaceuticals (SIX: SANN)
announced today that it will present data from the 2-year open-label study
(DELPHI-E study) evaluating Catena® for the treatment of Duchenne Muscular
Dystrophy [1], one of the most common and devastating types of muscular
dystrophy. The findings indicate that Catena® slowed the decline in respiratory
function compared to the expected natural history in patients with Duchenne
Muscular Dystrophy. Data from this study are in agreement with and confirm data
from a randomized controlled study (DELPHI study) of 12 months duration [2]. The
poster presentation will be given at the 16th International Congress of the
World Muscle Society in Almancil, Portugal on October 21, 2011.
http://www.cisionwire.com/santhera-pharmaceuticals-holding-ag-ext/r...
Sharon is attending WMS 2011. PRAYING TO GOD to hear many good news on Duchenne from WMS 2011.
Raktim
Replies to This Discussion
-
Permalink Reply by David on
-
Sharon,
The abstract you posted included this statement: The change over time in respiratory as well as cardiac function data will be presented.
Can PPMD post those changes?
-
Permalink Reply by Sharon Hesterlee on
-
Hi David:
I wasn't able to attend the Santhera presentation (I had to leave before the last day) so I don't have this information--I can email the company to see if they can send us the data.
Sharon
David said:Sharon,
The abstract you posted included this statement: The change over time in respiratory as well as cardiac function data will be presented.
Can PPMD post those changes?
- ‹ Previous
- 1
- 2
- Next ›
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
